Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
NCT03270007
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
304
Enrollment
OTHER
Sponsor class
Conditions
Primary Breast Cancer
Interventions
DRUG:
Vinorelbine
Sponsor
Tao OUYANG